Hexanedioic acid, compd. with 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine (1:2) manufacturers
- MAX-40279 hemiadipate
-
- $1860.00 / 100mg
-
2024-11-19
- CAS:2388506-44-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| Hexanedioic acid, compd. with 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine (1:2) Basic information |
| Hexanedioic acid, compd. with 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine (1:2) Chemical Properties |
storage temp. | Store at -20°C | solubility | DMSO : 25 mg/mL (42.76 mM; ultrasonic and warming and heat to 60°C)|DMF : 10 mg/mL (17.10 mM; ultrasonic and warming and heat to 60°C) | form | Solid | color | Off-white to light yellow |
| Hexanedioic acid, compd. with 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine (1:2) Usage And Synthesis |
Biological Activity | MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1]. | References | [1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1. |
| Hexanedioic acid, compd. with 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine (1:2) Preparation Products And Raw materials |
|